MarginsXMarginsX
Home › Markets › Health Care › KRYS

Krystal Biotech Inc. (KRYS)

KRYS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$297.90
-2.40% on the day
Market cap
$8.8B
Mid cap
Revenue · 2025
$389.1M
+33.9% on 2024
Net income · 2025
$204.8M
52.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1711279/000171127926000016/0001711279-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerKRYS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2017
SEC CIK0001711279
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$389.1M
Net income$204.8M
Operating income$161.3M
Net margin52.6%
Operating margin41.5%
Revenue growth+33.9%
Cash$496.3M
Total assets$1.3B
P/E (computed)43.1×
P/S (computed)22.7×

Warning signs

Cash runway
Cash-flow positive
$462.8M cash at September 30, 2026
Share count, 1 year
+2.2%
2025-10-29 to 2026-10-28 · +5.1% over 3 years
Going-concern doubt
No
10-Q filed November 2, 2026
Insider net buying, 12 months
-$95.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-02
Cash and burn$462.8M cash; operating cash flow $81.0M a quarter.Report 2026-09-30
Shares outstanding29,633,472 (2026-10-28); 28,997,519 a year earlier; 28,206,330 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Pittsburgh, Pennsylvania, United StatesPCAOB Form AP 2026-03-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $95.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$127.3M$63.1M$91.2M$462.8MNo debt tags$470.0M10-Q 2026-11-02
Q2 2026
2026-06-30
$119.2M$54.8M$74.8M$427.7MNo debt tags$440.5M10-Q 2026-08-03
Q1 2026
2026-03-31
$116.4M$55.9M$80.4M$501.3MNo debt tags$417.3M10-Q 2026-05-04
Q4 2025
2025-12-31
$107.1M$51.4M$77.5M$496.3MNo debt tags$389.1M10-K 2026-02-17
Q3 2025
2025-09-30
$97.8M$79.4M$39.7M$392.6MNo debt tags$373.2M10-Q 2026-11-02
Q2 2025
2025-06-30
$96.0M$38.3M$52.7M$353.8MNo debt tags$359.2M10-Q 2026-08-03
Q1 2025
2025-03-31
$88.2M$35.7M$31.0M$308.8MNo debt tags$333.4M10-Q 2026-05-04
Q4 2024
2024-12-31
$91.1M$45.5M$52.8M$344.9MNo debt tags$290.5M10-K 2026-02-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2023-07-18
Latest annual report10-K2026-02-17
Latest quarterly / interim10-Q2026-11-02
Latest current report8-K2026-11-02
Latest proxyDEFA14A2026-04-03

Source: SEC EDGAR submissions feed, 514 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.4%
1 month-5.0%
3 months-7.0%
Year to date+23.8%
1 year+51.7%
From 52-week high-19.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
RGENRepligen Corporation$162.78-2.99%$10.4B
KYMRKymera Therapeutics Inc.$125.85-1.35%$10.7B
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B
TWSTTwist Bioscience Corporation$105.04-5.88%$7.0B
IMVTImmunovant Inc.$33.28-2.63%$6.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier